Inverness Medical and BG MEDICINE to Develop Galectin-3 Test for Inverness’ Triage® Meter - Gilde Healthcare

Inverness Medical and BG MEDICINE to Develop Galectin-3 Test for Inverness’ Triage® Meter

April 26, 2010

Waltham, MA—BG Medicine, Inc. announced today that it has entered into an agreement with Inverness Medical Innovations, Inc. (NYSE: IMA)—a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health management—for the development and commercialization of a galectin-3 test for Inverness’ Triage Meter Pro. Galectin-3 is a novel biomarker that may play a role in detecting the development and progression of heart failure.

Under the agreement, Inverness will be responsible for the development of the test in accordance with certain plans and milestones, and Inverness and BG Medicine will collaborate in support of development of the test and regulatory filings.

“We look forward to the development of additional heart failure biomarker content, for use in conjunction with existing biomarkers, to enhance the assessment of this complex and costly medical condition,”

said Ron Zwanziger, President and CEO of Inverness.

“BNP and galectin-3 each provide important independent information about a patient’s heart failure.” said Pieter Muntendam, M.D., President and CEO of BG Medicine. “This business opportunity was created by the natural complementarity of the two tests.”

About Inverness Medical Innovations
By developing new capabilities in near-patient diagnosis, monitoring and health management, Inverness Medical Innovations enables individuals to take charge of improving their health and quality of life.  A global leader in rapid point-of-care diagnostics, Inverness’ products, as well as its new product development efforts, focus on infectious disease, cardiology, oncology, drugs of abuse and women’s health.  Inverness is headquartered in Waltham, Massachusetts.
 
About BG Medicine
BG Medicine is a life sciences company focused on the discovery, development, and commercialization of novel diagnostics based on biomarkers to improve patient outcomes and contain healthcare costs.

Gilde Healthcare company Volta Medical announces positive results from transatlantic trial on AI-assisted ablation for persistent atrial fibrillation

TAILORED-AF randomized controlled trial (RCT) findings demonstrated superiority in freedom from atrial fibrillation (AF) at 12 months from a tailored cardiac ablation guided by artificial intelligence (AI) when compared to pulmonary vein isolation (PVI) alone....
May 21, 2024

Gilde Healthcare co-leads $100M equity financing in Karius

Karius®, Inc., a world leader in genomic diagnostics for infectious disease, today announced it has secured $100 million in Series C funding. The round was co-led by Gilde Healthcare, Khosla Ventures and 5AM Ventures, and...
May 2, 2024

Gilde Healthcare company Ablative Solutions demonstrates Significant Reduction in Blood Pressure meeting its primary endpoint in Pivotal Trial

Ablative Solutions, Inc., announced that primary trial results from the TARGET BPI Pivotal Trial, evaluating alcohol-mediated renal denervation with the Peregrine SystemTM Kit, were presented as a Late-Breaking Clinical Trial at the American College of...
April 11, 2024